Details

Autor(en) / Beteiligte

• Bian, Yun
• Sun, Maoyun
• Silver, Marcy
• Ho, Kalon K. L
• Marchionni, Mark A
• Caggiano, Anthony O
• Stone, James R
• Amende, Ivo
• Hampton, Thomas G
• Morgan, James P
• Yan, Xinhua

Titel

Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins

Ist Teil von

• American journal of physiology. Heart and circulatory physiology, 2009-12, Vol.297 (6), p.H1974-H1983

Ort / Verlag

United States: American Physiological Society

Erscheinungsjahr

2009

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• 1 Cardiovascular Research, Caritas St. Elizabeth's Medical Center and Tufts University; 2 Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School; and 3 Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston; 4 Alzcor Therapeutics, Arlington, Massachusetts; and 5 Acorda Therapeutics, Hawthorne, New York Submitted September 17, 2008 ; accepted in final form September 11, 2009 Neuregulin-1 (NRG1) is a potential therapeutic agent for the treatment of doxorubicin (Dox)-induced heart failure. NRG1, however, activates the erbB2 receptor, which is frequently overexpressed in breast cancers. It is, therefore, important to understand how NRG1, via erbB2, protects the heart against Dox cardiotoxicity. Here, we studied NRG1-erbB2 signaling in Dox-treated mice hearts and in isolated neonatal rat ventricular myocytes (NRVM). Male C57BL/6 mice were treated with recombinant NRG1 before and daily after a single dose of Dox. Cardiac function was determined by catheterization. Two-week survival was analyzed by the Kaplan-Meier method. Cardiac troponins [cardiac troponin I (cTnI) and cardiac troponin T (cTnT)] and phosphorylated Akt protein levels were determined in mice hearts and in NRVM by Western blot analysis. Activation of caspases and ubiquitinylation of troponins were determined in NRVM by caspase assay and immunoprecipitation. NRG1 significantly improved survival and cardiac function in Dox-treated mice. NRG1 reduced the decrease in cTnI, cTnT, and cardiac troponin C (cTnC) and maintained Akt phosphorylation in Dox-treated mice hearts. NRG1 reduced the decrease in cTnI and cTnT mRNA and proteins in Dox-treated NRVM. Inhibition of erbB2, phosphoinositide 3-kinase (PI3K), Akt, and mTOR blocked the protective effects of NRG1 on cTnI and cTnT in NRVM. NRG1 significantly reduced Dox-induced caspase activation, which degraded troponins, in NRVM. NRG1 reduced Dox-induced proteasome degradation of cTnI. NRG1 attenuates Dox-induced decrease in cardiac troponins by increasing transcription and translation and by inhibiting caspase activation and proteasome degradation of troponin proteins. NRG1 maintains cardiac troponins by the erbB2-PI3K pathway, which may lessen Dox-induced cardiac dysfunction. ErbB2; troponin proteins; signaling Address for reprint requests and other correspondence: X. Yan, Cardiovascular Research, Caritas St. Elizabeth's Medical Center, 736 Cambridge St. CBR3, Boston, MA 02135 (e-mail: xinhua.yan{at}tufts.edu ).